8-K current report · filed Oct 23, 2026

Amneal Pharmaceuticals, Inc. (AMRX) 8-K Current Report: October 23, 2026

Item EX-99.1Item EX-99.2Item EX-99.3AMRX overview

Short answer

Amneal Pharmaceuticals, Inc. (AMRX) filed an 8-K current report with the SEC on October 23, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). Going-concern warning: $106.3M operating cash burn and $27.7M accumulated deficit create material funding risk through 2026.

Amneal Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item EX-99.1 · Exhibit EX-99.1

  • Going-concern warning: $106.3M operating cash burn and $27.7M accumulated deficit create material funding risk through 2026
  • $149.3M long-term debt added in 2025, increasing leverage despite $23.5M cash and restricted cash
  • Revenue rose to $80.0M from $37.7M, but research and development costs reached $99.2M
  • Net loss remained substantial at $109.1M, following a restated $124.7M loss in 2024
  • 2024 financial statements restated for misstatements, warranting heightened scrutiny of historical comparability and controls

Item EX-99.2 · Exhibit EX-99.2

  • Kashiv acquisition closed August 10, 2026, adding a wholly owned biopharmaceutical research, development and manufacturing business to Amneal
  • Consideration included $375 million cash, 28,942,108 Amneal shares and up to $350 million contingent regulatory milestones plus potential royalties
  • Six-month revenue fell to $27.3 million from $46.6 million, while net loss widened to $71.8 million from $38.3 million
  • Operating cash burn reached $68.2 million, with $158.1 million long-term debt and members’ deficit of $32.0 million
  • Substantial doubt about Kashiv’s standalone going-concern status, with management expecting Amneal support to fund operations through at least Q2 2027

Item EX-99.3 · Exhibit EX-99.3

  • Kashiv acquisition completed August 10, 2026 for preliminary aggregate consideration of $1.31B, including $491.6M equity and $266.1M closing cash
  • Amneal issued 28.9M Class A shares, creating dilution of approximately 9% versus pro forma basic shares of 342.3M
  • Funding added $350.0M term debt and $180.0M revolver borrowings, raising pro forma debt to $3.21B
  • Contingent consideration includes up to $350.0M milestone payments and royalties equal to 25% of excess annual gross profits for 12 years
  • Pro forma attributable loss was $78.2M for 2025 and income $17.2M for six months ended June 30, 2026, before potential synergies

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Amneal Pharmaceuticals, Inc. 8-K filings

Get the next AMRX 8-K as it lands

Follow AMRX for push alerts, or ask the research agent what this filing means.